Neovasc — Non-Deal Roadshow (June 2008)
34 slides from Neovasc's roadshow presentation, June 2008
Slide 1: Neovasc Inc.
Neovasc Inc. June, 2008 Alexei Marko, CEO Chris Clark, CFO
Slide 2: Forward-Looking Statements
Forward-Looking Statements Statements contained herein that are not based on historical or current fact, including without limitation statements containing the words “anticipates,” “believes,” “may,” “continues,” “estimates,” “expects,” and “will” and words of similar import, constitute “forward-loo
Slide 3: Agenda
Agenda > Neovasc today Product platforms Growth drivers Financial highlights
Slide 4: Neovasc at a Glance
Neovasc at a Glance • Medical device company focused on solving clinical problems for MDs in the vascular field • Targeting large underserved markets – Peripheral artery disease (PAD) – Refractory angina • Initial products approved in US/EU and generating early sales (~$1.5M in 2007) • Strong pipeli
Slide 5: Mission
Mission • Neovasc develops vascular devices for use by interventional cardiologists and radiologists, and vascular surgeons. • We focus on devices that solve clinical problems and benefit medical practice by making patient care faster, easier and more effective.
Slide 6: Company Origin
Company Origin Medical Ventures Corp. (Vancouver, Canada) TSXV: MEV AMEX application • Metricath arterial catheters • PeriPatch surgical tissue Neovasc Medical Ltd. B-Balloon Ltd. (Israel) (Israel) • vascular catheter technologies • vascular catheter technologies July 1, 2008
Slide 7: Target Markets
Target Markets Disease Market Size Customers Cardiovascular US ~16M people • Cardiovascular surgeons Disease (CVD) US ~1.2M new/yr • Vascular surgeons $156B US overall cost • Interventional cardiologists $18B US devices • Interventional radiologists Peripheral Artery US ~8M people • Vascular surgeon
Slide 8: Clinical Advisors
Clinical Advisors Our Advisors include leading practitioners and opinion leaders Metricath Ostial Products Reducer Dr. David Allie* Dr. Gary Ansel Dr. Shmuel Banai* Dr. Rajesh Dave* Dr. Arik Finkelstein* Dr. Robert Bonow* Dr. Jorge Saucedo Dr. Michael Jaff Dr. Elazar Edelman* Dr. Robert Tahara* Dr.
Slide 9: Management and Board
Management and Board Management Board of Directors Alexei Marko - CEO Paul Geyer (Chairman) Chris Clark - CFO Steve Rubin Eyal Sandach – Exec VP Israel Doug Janzen Brian McPherson – VP Operations Boaz Lifschitz Sean Moore – VP Sales Bill O’Neill MD Cynthia Roney – VP Marketing Dr. Jane Hsiao Amir Mi
Slide 10: Agenda
Agenda Neovasc today > Product platforms Growth drivers Financial highlights
Slide 11: Two Growth Platforms
Two Growth Platforms Interventional Products Surgical Products Products for use during Products for use during open catheter-based treatment of or minimally invasive surgical vascular disease procedures
Slide 12: Interventional Products
Interventional Products Metricath® Arterial Measurement System • Precise measurement of arteries and stents for device selection and optimization • Fast and cost effective • FDA cleared and EU approved Ostial Dilatation balloons and stent systems for “ostial” locations Products • Enable precise plac
Slide 13: Metricath
Metricath • Console and disposable balloon catheters • Precise artery and stent lumen size measurements for: - selecting stent or treatment catheter size - ensuring complete stent expansion • Metricath Libra “measure only” product FDA cleared and CE marked • Metricath Gemini “measure-and-treat” prod
Slide 14: Ostial Products
Ostial Products Difficult to properly locate a stent or balloon at the origin of an artery where it branches from the aorta (“the ostium”) • Time consuming and frustrating for MD’s • ~200,000 ostial lesions treated annually in US X X • risk of clots • artery still blocked • can’t re-access
Slide 15: Ostial Products
Ostial Products Dual balloon system guides precise placement of balloon or stent at the ostium • Significantly reduces procedure time and hassle for MD • Reduces potential complications and/or need for multiple treatments • First ostial balloon products into US market in 2009 • First ostial stent sy
Slide 16: Reducer
Reducer • Treats refractory angina – chronic heart pain from inadequate blood flow - ~2M patients in the US - drugs not providing relief - stents / surgery failed or not an option • Implanted in the coronary sinus to restrict outflow from coronary arteries • Resulting back-pressure improves blood fl
Slide 17: Reducer
Reducer • Compelling clinical data from first human trial - published in JACC - No device related adverse events or complications - Significant improvement in majority of subjects • Filing for EU approval in 2009 • Initial plan in place for US FDA trial (PMA trial) • Key US trial investigators ident
Slide 18: Surgical Products
Surgical Products PeriPatch™ Tissue for surgical repair • Used as general patch material • 20+ year implant history • “Remodelable” version in 2009 Vascufix™ Peripheral vascular patch • Used for peripheral repair • 20+ year implant history • Targets carotid EA and related procedures Aegis™ Staple li
Slide 19: PeriPatch
PeriPatch • Cross-linked bovine and equine pericardial tissue • Treatment process creates implantable, biocompatible collagen tissue that retains physical characteristics of natural tissue • Initially developed for heart valve applications (20+ year implant history) • Adapted for general surgical us
Slide 20: VascuFix
VascuFix • Implantable tissue patches tailored specifically for peripheral vascular repair procedures • Thin, uniform tissue ideal for precision applications such as artery repair • Same mft. process as PeriPatch • Primary use is for carotid endarterectomies (150k cases/year in US) • FDA cleared
Slide 21: Aegis
Aegis • Used in minimally invasive thoracic and bariatric surgery (200k/yr bariatric surgeries in US, growing @30%) • Buttress of tissue under staples to minimize leakage of blood/fluid (a major complication in bariatric surgery) • Does not dislodge during manipulation • Fits standard Ethicon & US S
Slide 22: Contract Services
Contract Services • OEM tissue supply to multiple endovascular valve companies • Contract manufacturing • Product development services Provides near term revenue generation with significant potential for future growth
Slide 23: Sales Channels
Sales Channels Product Distribution Strategy US • Interventional Direct • Reps located in key markets products • Situated near multiple hospitals • VascuFix • Call on interventionists AND surgeons • Developing early customers and markets for initial products • Expand sales force in 2009 as new produ
Slide 24: Intellectual Property
Intellectual Property • Strong IP in place or pending to protect catheter products • Combination of trade secrets and patent protection for tissue products • Freedom to practice opinions obtained for Metricath, Ostial and Reducer products
Slide 25: Agenda
Agenda Neovasc today Product platforms > Growth drivers Financial highlights
Slide 26: Market Drivers
Market Drivers 1. Aging population and better management of coronary vascular disease results in growing incidence of peripheral artery disease and refractory angina 2. Physicians seeking better clinical tools to ease and speed procedures 3. Trend to “hybrid” MD’s who perform both catheter- based an
Slide 27: Growth Strategy
Growth Strategy Effectively commercialize a portfolio of vascular products though both internal development and strategic acquisition • Increased bandwidth for research and development through Israeli acquisitions • Suppressed acquisition environment and buyers market for pre- or early-commercial te
Slide 28: Value Building Events
Value Building Events 2008 2009 2010 2nd half 1st half 2nd half 1st half AMEX Listing X Metricath Gemini FDA approval X Ostial Balloon products approved in EU X Ostial Balloon products approved in US X Ostial Stent products approved in EU X Remodelable tissue approved in US X Reducer CE mark applica
Slide 29: Agenda
Agenda Neovasc today Product platforms Growth drivers > Financial highlights
Slide 30: Historical Revenues
Historical Revenues Year over Year Revenue Growth 1600 1400 1200 1000 $000s 800 600 400 200 0 2006 2007 Contract 179 308 Vascular 187 258 Surgical 717 952 Year
Slide 31: Balance Sheet
Balance Sheet DRAFT BALANCE SHEET* $Ms CURRENT ASSETS • Concurrent financing $8.3m, CASH 8.5 sufficient runway for next ACCOUNTS RECEIVABLE 0.5 financing in the first half of 2009 INVENTORY 0.5 PROPERTY 1.5 • Intangible assets includes INTANGIBLE ASSETS 24.5 acquired technologies, patents 35.5 and r
Slide 32: Capitalization
Capitalization* Shares outstanding ~ 17.7M ~ 22.9M (fully diluted) July 1 financing terms • Private placement for ~$8.3M at $4.00 per unit • Unit comprises 1 common share with 4 month hold, and 0.62 warrants (18 month, $5.00 exercise price) Estimated market capitalization • $55M (Based on 6 month av
Slide 33: Summary
Summary Underserved and growing markets Market Focus in vascular medicine Growth in PAD and evolution of Market opportunity vascular practices Develop & acquire suite of Business model products to meet needs of MDs Experienced management, Leadership directors and clinical advisors Strong technology
Slide 34: Slide 34